Methylenedioxymethamphetamine (ecstasy)-related hyperthermia.

[1]  Michael Shannon,et al.  The serotonin syndrome. , 2005, The New England journal of medicine.

[2]  G. Goodwin,et al.  Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) , 1995, Psychopharmacology.

[3]  M. Colado,et al.  The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 2003, Pharmacological Reviews.

[4]  H. Kalant,et al.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[5]  R. Tyndale,et al.  Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. , 2001, Pharmacogenetics.

[6]  M. Baggott,et al.  Chemical analysis of ecstasy pills. , 2000, JAMA.

[7]  A. Somogyi,et al.  Acute Toxicity of 3,4-Methylenedioxymethamphetamine (MDMA) in Sprague–Dawley and Dark Agouti Rats , 1999, Pharmacology Biochemistry and Behavior.

[8]  P D Mueller,et al.  Death by "ecstasy": the serotonin syndrome? , 1998, Annals of emergency medicine.

[9]  R. Byard,et al.  Amphetamine derivative fatalities in South Australia--is "Ecstasy" the culprit? , 1998, The American journal of forensic medicine and pathology.

[10]  A. Mallick,et al.  MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. , 1997, Journal of accident & emergency medicine.

[11]  G. Tucker,et al.  Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[12]  P. Gillman.  Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. , 1997, Medical Journal of Australia.

[13]  R. Dowsett.  Deaths attributed to “ecstasy” overdose , 1996, Medical Journal of Australia.

[14]  J. Coore,et al.  A Fatal Trip with Ecstasy: A Case of 3,4-Methylene-Dioxymethamphetamine/ 3,4-Methylenedioxy-Amphetamine Toxicity , 1996, Journal of the Royal Society of Medicine.

[15]  M. Colado,et al.  The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype , 1995, British journal of pharmacology.

[16]  G. Lavery,et al.  Malignant hyperpyrexia in an MDMA ("Ecstasy") abuser. , 1994, The Ulster medical journal.

[17]  G. Tucker,et al.  The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). , 1994, Biochemical pharmacology.

[18]  A. Bodenham,et al.  Hyperthermia associated with 3,4‐methylenedioxyethamphetamine (‘Eve’) , 1993, Anaesthesia.

[19]  A. Larner.  Dantrolene and ‘ecstasy’ overdose , 1993, Anaesthesia.

[20]  S. Dawling,et al.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.

[21]  G. Screaton,et al.  Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse , 1992, The Lancet.